4-(4-Aethyl-phenyl)-buttersaeure-aethylester | 412321-18-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-(4-Aethyl-phenyl)-buttersaeure-aethylester
• 英文别名: 4-(4-ethyl-phenyl)-butyric acid ethyl ester；ethyl 4-(4-ethylphenyl)butyrate；ethyl 4-(4-ethylphenyl)butanoate
• CAS: 412321-18-7
• 化学式: C₁₄H₂₀O₂
• 分子量: 220.312
• InChiKey: WYYKCJIBJHKZKS-UHFFFAOYSA-N

物化性质

• 沸点：
  146-147 °C(Press: 8 Torr)
• 密度：
  0.980±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-Aethyl-phenyl)-buttersaeure-aethylester 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 4-(4-乙基苯)丁酸
  参考文献：
  名称：

  WO2008/112368

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(4-乙基苯)丁酸 生成 4-(4-Aethyl-phenyl)-buttersaeure-aethylester
  参考文献：
  名称：

  200.苯并蒽酮。第二部分 3'-烷基内消旋苯并蒽醌的合成。关于巴利反应机理的进一步观察

  摘要：

  DOI：

  10.1039/jr9390000944

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• HETEROCYCLIC CETP INHIBITORS
  申请人：Salvati E. Mark

  公开号：US20070161685A1

  公开（公告）日：2007-07-12

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
• N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES
  申请人：Salvati Mark E.

  公开号：US20100041717A1

  公开（公告）日：2010-02-18

  Compounds of formula (Ia) and (Ib), wherein A, B, C, R 1 and R 14 are described herein.

  式(Ia)和(Ib)的化合物，其中A、B、C、R1和R14如本文所述。
• Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
  申请人：Nakai Hisao

  公开号：US20080027094A1

  公开（公告）日：2008-01-31

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R 1 , R 2 , R 3 and R 1 each a hydrogen atom or a substituent; R 5 is a substituent; X − is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的通过吸入途径给药的抗胆碱药物被认为可能会加重与前列腺增生有关的排尿困难，因此要求传统的通过吸入途径给药的抗胆碱药物必须显示出减少的副作用或不良反应。本发明涉及一种由通式（I）表示的化合物：（其中A表示；R1、R2、R3和R4分别表示氢原子或取代基；R5表示取代基；X-表示阴离子；符号：表示外部形式或内部形式，或它们的混合物），其盐或溶剂化产物。它们可用作具有减少副作用或不良反应的预防和/或治疗剂，用于由肌肉性受体介导的疾病。
• PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS
  申请人：Gschneidner David

  公开号：US20110046050A1

  公开（公告）日：2011-02-24

  The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.

  本发明提供苯基烷基羧酸化合物及含有此类化合物的组合物，有助于传递生物活性物质。